Search

Displaying results 821 - 830 of 3872 in total
  1. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  2. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    Cenegermin received approval from the US FDA a year later in August of 2018. [L4563] Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. … Many currently available therapeutic options for treating the condition involve surgical interventions - surgeries that are typically only palliative [L4563].

  3. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.

  4. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]

  5. Drug

    Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14457
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: Medical Provider Single Use EZ Flu Shot Fluzone 2016-2017
  6. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from

    Products: EPOTREX-NP
  7. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Pibrentasvir is available as an oral combination therapy with [DB13879] under the brand name Mavyret. … In combination with [DB13879], pibrentastiv is a useful therapy for patients who experienced therapeutic failure from other NS5A inhibitors.

  8. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    The remaining amount of the drug substance contains undefined botanical constituents derived from green tea leaves. … It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components.

  9. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells

  10. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.